Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?
Life · 12.05.2026 · 16 (5) · 802
DOI: 10.3390/life16050802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Life, online erschienen am 12.05.2026. Verfasst von Florin-Dumitru Mihălțan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardio-Thoracic Pathology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania. Die Arbeit nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Obesity is a major driver of obstructive sleep apnea (OSA), traditionally managed as a mechanical disorder of upper airway collapse. However, growing evidence supports a broader pathophysiological model involving metabolic dysfunction, systemic inflammation, and ventilatory instability. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated substantial weight loss and cardiometabolic benefits, raising the possibility of a paradigm shift in OSA management.
Objective
To critically evaluate whether tirzepatide may act as a disease-modifying therapy in obesity-related OSA beyond its effects on weight reduction.
Methods
A narrative review was conducted using PubMed, Scopus, and Web of Science up to January 2026. Evidence from randomized controlled trials, meta-analyses, and mechanistic studies on incretin-based therapies in obesity and OSA was synthesized, with emphasis on clinical outcomes and underlying biological pathways.
Results
Tirzepatide is associated with significant reductions in apnea–hypopnea index (AHI), accompanied by substantial weight loss. However, emerging data suggest that improvements in OSA severity may not be entirely explained by weight reduction alone. Potential weight-independent mechanisms include modulation of systemic inflammation, improvements in insulin sensitivity, alterations in adipokine profiles, and effects on autonomic regulation and ventilatory control. These pleiotropic effects may influence key components of OSA pathophysiology, including upper airway stability and chemosensitivity. Despite these findings, current evidence remains insufficient to definitively distinguish weight-dependent from weight-independent effects.
Conclusions
Tirzepatide represents a promising therapeutic advance in obesity-related OSA, with potential implications extending beyond weight loss toward disease modification. While current data support a substantial role in reducing OSA severity, definitive confirmation of disease-modifying effects requires further mechanistic and long-term clinical studies. This emerging paradigm points to a shift from purely device-based management toward integrated, pathophysiology-driven treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardio-Thoracic Pathology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
- Institute of Pneumology "Marius Nasta", 050159 Bucharest, Romania.
ORCID-Profile: Ancuța Alina Constantin
Zitieren
APA
Mihălțan, F. D., Borcea, C. I., & Constantin, A. A. (2026). Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?. Life, 16(5), 802. https://doi.org/10.3390/life16050802
Vancouver
Mihălțan FD, Borcea CI, Constantin AA. Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?. Life. 2026;16(5):802. doi:10.3390/life16050802
BibTeX
@article{Mihlan2026,
author = {Mihălțan, Florin-Dumitru and Borcea, Corina Ioana and Constantin, Ancuța Alina},
title = {Tirzepatide in Obesity-Related Obstructive Sleep Apnea: Beyond Weight Loss Toward Disease Modification?},
journal = {Life},
year = {2026},
volume = {16},
number = {5},
pages = {802},
doi = {10.3390/life16050802}
}
EUVIMED